METHOD OF TREATING HYPERGLYCEMIA

• US 20190321327A1
• Filed: 03/25/2019
• Published: 10/24/2019
• Est. Priority Date: 04/20/2018
• Status: Abandoned Application

• Current Assignee: Center Laboratories, Inc.
• Original Assignee: Center Laboratories, Inc.
• Inventors: HSU, Jui-Pao, SHANE, Guang-Tzuu, LEE, Meng-Ju, LIAO, Yi-Ping, YEH, Yu-Yin, CHANG, Shu-Hsien
• Application Number:
  US16/364,121
• Publication Number:
  US 20190321327A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 31/277 having a ring, e.g. verapamil
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics

Abstract

Disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. In particular, the present invention relates to methods of using (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof and insulin or an insulin analogue in the treatment of mellitus and/or disorders related to diabetes mellitus.

Claims

1. A method of treating a subject having diabetes mellitus and/or disorders related to diabetes mellitus comprising administering to the subject an effective amount of (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof, and insulin or an insulin analogue.

2. The method of claim 1, wherein the insulin analogue is glargine, degludec or detemir.

3. The method of claim 2, wherein the insulin analogue is glargine.

4. The method of claim 1, wherein the (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof is administered to the subject in the amount of 15 to 1,000 mg/day;

and the insulin or the insulin analogue is administered to the subject in the amount of 0.05 to 3 units/kg/day.

5. The method of claim 4, wherein the (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof is administered to the subject in the amount of 25 to 800 mg/day;

and the insulin or the insulin analogue is administered to the subject in the amount of 0.1 to 2 units/kg/day.

6. The method of claim 1, wherein the (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof is administered to the subject in single or divided doses 2 or 3 times each day;

and the insulin or the insulin analogue is administered to the subject in single or divided doses 2 or 3 times each day.

7. A pharmaceutical composition for the treatment of diabetes mellitus and/or disorders related to diabetes mellitus comprising:

(R)-(+)-verapamil or a pharmaceutically acceptable salt thereof;

insulin or an insulin analogue; and

a pharmaceutically acceptable excipient.

8. The pharmaceutical composition of claim 7, wherein the insulin analogue is glargine, degludec or detemir.

9. The pharmaceutical composition of claim 8, wherein the insulin analogue is glargine.

10. (canceled)